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Abstract
Background: Artemether-lumefantrine is one of the most widely used anti-malarial drug combinations in the
world with excellent tolerability and cure rates in adult and paediatric patients with uncomplicated falciparum
malaria. The aim of this study was to evaluate the pharmacokinetics of artemether and its active metabolite,
dihydroartemisinin, in healthy Pakistani volunteers.
Methods: Twelve healthy male Pakistani subjects, aged 20 to 50, were recruited into the study. A fixed oral
combination of artemether-lumefantrine (80-480 mg) was given as a single oral dose. Frequent blood samples
were collected and artemether and dihydroartemisinin were quantified in human plasma using solid-phase
extraction and liquid chromatography coupled with tandem mass spectrometry. Drug concentration-time data
were evaluated with non-compartmental analysis.
Results: Observed maximum concentrations (mean ± SD) of artemether and dihydroartemisinin were 184 ± 100
ng/mL and 126 ± 46 ng/mL, respectively. These concentrations were reached at 1.56 ± 0.68 hr and 1.69 ± 0.59 hr,
respectively, after drug intake. The terminal elimination half-life of artemether and dihydroartemisinin were 2.00 ±
0.71 hr and 1.80 ± 0.31 hr, respectively. Apparent volume of distribution and oral clearance for artemether were
estimated to 666 ± 220 L and 257 ± 140 L/hr. The same parameters were estimated to 702 ± 220 L and 269 ± 57
L/hr for dihydroartemisinin.
Conclusions: The overall pharmacokinetic properties of artemether and dihydroartemisinin in healthy Pakistani
subjects are comparable to healthy subjects and patients from other populations.
Background
Malaria is one of the most important infectious diseases
in the world. This parasitic disease caused almost one
million deaths in 2006, mostly children under the age of
5 [1]. Artemisinin is a natural anti-malarial derived from
the Chinese medicinal plant Artemisia annua. The arte-
misinin derivatives are the most effective anti-malarial
drugs available today and they have been used with suc-
cess in areas with multidrug resistant Plasmodium falci-
parum m a l a r i a[ 2 - 8 ] .T h e s ec o m p o u n d sg i v ear a p i d
reduction in parasite biomass and consequently a rapid
resolution of symptoms [9]. Artemisinin based combina-
tion therapy (ACT) is now recommended as first-line
treatment worldwide and used to treat millions of
malaria patients each year.
Exafal™ is a fixed-dose ACT formulation of artemether
and lumefantrine, with each tablet containing 20 mg
artemether and 120 mg lumefantrine. The recom-
mended treatment is four tablets twice a day for three
days (administered at 0, 8, 24, 36, 48, and 60 hr). This
anti-malarial is generally well tolerated and highly effica-
cious in adults and children with uncomplicated falci-
parum malaria [2-8]. Recent reports have shown lower
cure rates in pregnant women with uncomplicated falci-
parum malaria due to lower drug concentrations of arte-
mether, dihydroartemisinin and lumefantrine [10-12].
Artemether is rapidly absorbed and extensively metabo-
lized (i.e. demethylated) in vitro by the cytochrome
P450 (CYP) enzymes CYP1A2, CYP2B6, CYP2C19 and
CYP3A4 into dihydroartemisinin [13,14]. However, no
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in the demethylation of artemether in healthy volunteers
[14]. Dihydroartemisinin (geometric mean IC50-value of
1.2 ng/mL) is intrinsically more active than artemether
(geometric mean IC50-value of 4.8 ng/mL) as an anti-
malarial when investigated in fresh clinical falciparum
isolates on the Thai-Burmese border [15].
Different human CYP content and isoform capacity
has generally been attributed to genetic factors [16].
This contributes to the wide variety in drug metabolism
capacity among different individuals and populations.
This is especially true for CYP3A4 and CYP2 D and
drugs cleared by these isoforms might therefore be
expected to show highly variable pharmacokinetics [17].
Artemether and dihydroartemisinin show large inter-
individual variability in pharmacokinetic parameters.
T h i sm a yi ns o m ep a r tb ee x p l a i n e db yg e n e t i cd i f f e r -
ences in different individuals and populations. Inter-eth-
nic variability might therefore be an important factor
when accounting for inter-individual variability in drug
response [18]. The pharmacokinetics of artemether and
dihydroartemisinin is described in a number of different
populations, such as Caucasians [19], Thais [20], Chi-
nese [21] and Malaysians [22]. However, the pharmaco-
kinetics of artemether and dihydroartemisinin has not
yet been studied in a Pakistani population.
The objective of this study was to characterize the
pharmacokinetics of artemether and dihydroartemisinin
in healthy Pakistani male subjects after a single oral
administration of the standard fixed artemether-lume-
fantrine anti-malarial combination treatment.
Methods
Study site and ethical approval
Twelve healthy Pakistani male subjects aged 20 to 50
years were enrolled in this study, conducted at the
Department of Pharmacology and Therapeutics, Centre
for Research in Experimental and Applied Medicine
(CREAM), Army Medical College, Rawalpindi, Pakistan.
The study protocol was approved by the Research Ethics
Committee at the National University of Sciences and
Technology, Islamabad, Pakistan. The purpose of the
study, potential discomfort and adverse events were
carefully explained to the volunteers in their own lan-
guage and written consent was obtained. Physical and
laboratory examinations were performed which included
screening for cardiovascular, renal, hepatic and/or gas-
trointestinal disorders. The exclusion criteria were clini-
cally significant ECG abnormalities, smoking, known
renal or hepatic dysfunction. None of the volunteers
had a recent history (< 3 months) of taking anti-malar-
ials or concurrent medications. Only those who wilfully
consented to participate and that fulfilled all of the
inclusion criteria and none of the exclusion criteria were
enrolled in the study.
Study drug
Four tablets of artemether-lumefantrine (Exafal™: each
tablet contains 20/120 mg artemether/lumefantrine),
produced by Novartis, Karachi, Pakistan were adminis-
tered as a single oral dose. The drug was taken with a
glass of milk (250 mL) after an overnight fast. The
volunteers were provided a high fat traditional breakfast
(i.e. Cheese omelette, fried wheat flour bread, meat
gravy, and lentils) one hr after the drug administration.
Relative bioavailability of artemether and lumefantrine
has been demonstrated to increase with more than two-
fold and five-fold, respectively, when administered with
a high fat (> 1.2 g) meal compared with that in fasted
individuals [23,24].
Plasma sample collection
Blood samples for drug quantification were taken from
an indwelling venous canula during the first 12 hr and
thereafter by direct venipuncture. Five milliliters of
blood were collected on each occasion in lithium-hepar-
inized tubes and centrifuged without delay at 2,200 g for
five minutes at 4°C. The plasma was kept in polypropy-
lene screw capped tubes at -80°C until analysed. Blood
samples were taken from each individual pre-dose (0 hr)
and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8,
12, and 24 hr post-dose.
Drug analysis
This study was conducted in January 2008 and plasma
samples were sent on dry-ice to the Clinical Pharmacol-
ogy Laboratory at the Faculty of Tropical Medicine,
Mahidol University, Bangkok, Thailand for artemether
and dihydroartemisinin quantification (June 2008). Arte-
mether and dihydroartemisinin are stable for at least
two years at -80°C (in-house validation data and also to
be part of an upcoming WHO report from the consen-
sus meeting on the assessment of anti-malarial drug
exposure in clinical trials). Plasma samples were ana-
lysed using high throughput liquid chromatography with
tandem mass spectrometry [25]. Briefly, artemether and
dihydroartemisinin were extracted using solid phase
extraction (Oasis HLB μ-elution plate, Waters, Milford,
USA) and quantified on an API 5000™ triple quadruple
mass spectrometer (Applied Biosystems/MDS SCIEX,
Foster City, USA), with a TurboV ionisation source
(TIS) interface operated in the positive ion mode. Stable
isotope labelled artemether and dihydroartemisinin were
used as internal standards. Selected reaction monitoring
(SRM) was used during quantification; transitions m/z
316-163 (artemether), m/z 320-163 (stable labelled
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307-166 (stable labelled dihydroartemisinin). The liquid
chromatographic (LC) system was an Agilent 1200 sys-
t e m( A g i l e n tt e c h n o l o g i e s, Santa Clara, USA). Data
acquisition and quantification were performed using
Analyst 1.4 (Applied Biosystems/MDS SCIEX, Foster
City, USA). The lower limit of quantification (LLOQ)
for both artemether and dihydroartemisinin was set to
1.43 ng/mL with a limit of detection of 0.5 ng/mL. Tri-
plicates of quality control samples at 3.46 ng/mL, 36 ng/
mL, and 375 ng/mL for artemether and dihydroartemisi-
nin were analysed in each batch during routine drug
analysis.
Pharmacokinetic analysis
Pharmacokinetic characterization of artemether and dihy-
droartemisinin was performed using non-compartmental
analysis (WinNonlin 5.0, Pharsight Corporation, Ca, USA).
Artemether was assumed to be fully transformed into
dihydroartemisinin in vivo and the relative difference in
molecular weights between dihydroartemisinin and arte-
mether were used to compute the putative dose of admi-
nistered dihydroartemisinin (i.e. 95.5% of artemether dose)
[13]. Pharmacokinetic analysis was performed using the
linear-up/log-down trapezoidal method for each indivi-
dual concentration-time profile. Total drug exposure
(AUC0-∞) was calculated for each subject with extrapola-
tion to time infinity by CPRED/lZ,w h e r eC PRED is the
predicted concentration at the time for the last observed
concentration and lZ is the elimination rate constant
during the terminal phase. The terminal elimination half-
life (t1/2) was determined by log-linear regression of 4 to
7 observed concentrations. Maximal concentration
(CMAX) and time to reach maximal concentration
(TMAX) were taken directly from the observed data. Oral
clearance (CL/F) and apparent oral volume of distribu-
tion (VZ/F) are also reported.
Results
The oral formulation of artemether was well-tolerated
and no clinical adverse effects were observed in any of
the study subjects. Artemether and dihydroartemisinin
were quantified in a total of 216 plasma samples in
twelve healthy Pakistani subjects after a single oral dose
of artemether-lumefantrine (80/480 mg artemether/
lumefantrine). Of these, 44 artemether concentrations
and 52 dihydroartemisinin concentrations (not including
pre-dose) were determined to be below the LLOQ.
Total precision (%CV) of quality control samples during
analysis were determined to 4.7%, 1.4% and 1.5% for
artemether and to 3.0%, 1.6% and 0.7% for dihydroarte-
misinin in low, mid and high (i.e. 3.46 ng/mL, 36 ng/mL
and 375 ng/mL) quality control samples.
Individual plasma concentration-time profiles were
evaluated in all twelve subjects for artemisinin and dihy-
droartemisinin using non-compartmental analysis (Table
1). Pharmacokinetics was well described but showed
large inter-individual variability. One observed
Table 1 Non-compartmental analysis of artemether and dihydroartemisinin pharmacokinetics in twelve healthy
Pakistani subjects
Artemether Dihydroartemisinin
Mean ± SD Median (range) Mean ± SD Median (range)
Body-weight (kg) 69.9 ± 10 69.0 (51.0-83.0) 69.9 ± 10 69.0 (51.0-83.0)
Dose (mg/kg) 1.17 ± 0.18 1.16 (0.960-1.57) 1.11 ± 0.17 1.10 (0.92-1.49)
TLAG (hr) 0.130 ± 0.23 0 (0-0.75) 0.250 ± 0.24 0.250 (0-0.75)
CMAX (ng/mL) 184 ± 100 173 (54.2-363) 126 ± 46 122 (53.7-195)
CMAX/dose (kg × ng/mL × mg) 160 ± 86 148 (34.6-299) 113 ± 38 107 (57.1-169)
TMAX (hr) 1.56 ± 0.68 1.50 (0.500-3.00) 1.69 ± 0.59 1.50 (0.750-3.00)
CL/F (L/hr) 257 ± 140 222 (119-609) 269 ± 57 246 (209-383)
CL/F (L/hr × kg) 3.89 ± 2.8 3.11 (1.57-11.9) 3.87 ± 0.74 3.70 (3.05-5.27)
VZ/F (L) 666 ± 220 651 (342-1150) 702 ± 220 643 (456-1190)
VZ/F (L/kg) 9.85 ± 4.5 8.68 (5.02-22.5) 10.1 ± 2.6 9.63 (6.61-14.6)
T1/2 (hr) 2.00 ± 0.71 1.88 (1.24-4.00) 1.80 ± 0.31 1.78 (1.34-2.20)
AUC0-LAST (hr × ng/mL) 379 ± 170 362 (128-664) 287 ± 60 303 (196-361)
AUC0-∞ (hr × ng/mL) 385 ± 170 370 (131-671) 294 ± 58 311 (199-365)
AUC0-∞/dose (kg × hr × ng/mL × mg) 339 ± 160 322 (83.8-638) 267 ± 48 270 (190-327)
Extrapolated AUC0-∞ (%) 1.75 ± 0.99 1.43 (0.90-4.26) 2.59 ± 2.2 1.71 (0.73-8.76)
TLAG = absorption lag time, CMAX = maximum observed plasma drug concentration, TMAX = observed time to reach CMAX, CL/F = oral clearance, VZ/F = apparent
oral volume of distribution based on the terminal phase, T1/2 = terminal elimination half-life, AUC0-LAST = area under the plasma concentration time curve after
the first dose to the last sampling time, AUC0-∞ = area under the plasma concentration time curve after the first dose to infinity, and Extrapolated AUC0-∞ =
percentage of AUC0-∞ due to extrapolation from last measured concentration to infinity.
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and removed before analysis (i.e. >10-fold unexplained
increase and decrease around data point six hr after
dose). Individual artemether and dihydroartemisinin
plasma concentration-time curves are shown in Figure 1.
Artemether (80 mg per adult dose) was absorbed
rapidly from the gastrointestinal tract with a lag-time of
up to 45 minutes. Considerable fluctuations in plasma
artemether and dihydroartemisinin concentrations were
observed within and between patients resulting in large
inter-individual variability in pharmacokinetic para-
meters. CMAX (mean ± SD) for artemether and dihy-
droartemisinin were 184 ± 100 ng/mL and 126 ± 46 ng/
mL, respectively. CMAX was reached after 1.56 ± 0.68 hr
for artemether and 1.69 ± 0.59 hr for dihydroartemisinin
after drug administration. AUC0-∞,C L / F ,V Z/F and t1/2
for artemether were 385 ± 170 hr × ng/mL, 257 ± 140
L/hr, 666 ± 220 L, and 2.00 ± 0.71 hr, respectively,
while computed parameters for dihydroartemisinin were
294 ± 58 hr × ng/mL, 269 ± 57 L/hr, 702 ± 220 L, and
1.80 ± 0.31 hr, respectively. The mean percentage of
total AUC0-∞ extrapolated to infinity was below 3% for
both artemether and dihydroartemisinin.
Discussion
The concentration-time profiles of artemether and dihy-
droartemisinin were evaluated in all of the 12 healthy
male Pakistani volunteers and showed similar pharma-
cokinetics as reported in other populations with differ-
ent ethnicity (Table 2) [19-22]. Artemether shows a
Figure 1 Pharmacokinetic profiles. Individual drug plasma concentration-time profiles for artemether (A) and dihydroartemisinin (B) in healthy
Pakistani volunteers after a single oral dose of 80 mg artemether and 480 mg lumefantrine. Drug concentrations are plotted on a logarithmic
scale with the base 10.
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tions. Maximal drug concentration and total drug expo-
sure of artemether and dihydroartemisinin are generally
comparable between the different healthy populations.
However, Na-Bangchang et al [20] report a slightly
longer median artemether terminal elimination half-life
but a more than five-fold longer terminal elimination
half-life for dihydroartemisinin in both healthy Thai
volunteers and Thai patients than reported in other
populations. This results in an approximately 10-fold
higher total dose-normalized exposure of dihydroartemi-
sinin [20]. To the best of our knowledge, this long half-
life has not been reproduced elsewhere. This could pos-
sibly be related to drug assay differences. Contradictory
to that report, Lefevre et al [26] report similar maxi-
mum concentration and total drug exposure in 25 Thai
patients with uncomplicated falciparum malaria as seen
in the healthy Pakistani volunteers in this study. Total
Table 2 Pharmacokinetic parameter estimates for artemether and dihydroartemisinin in different ethnic populations
after artemether administration
Pakistani male
healthy
volunteers
(n = 12).
Oral single dose
of 80 mg
artemether
a,b
[present study]
Caucasian male
and female healthy
volunteers
(n = 16).
Oral single dose of
80 mg artemether
a,b [19]
Thai male healthy
volunteers (n = 6).
Oral single dose of
200 mg
artemether
c [20]
Malaysian male
healthy volunteers
(n = 6).
Oral single dose of
200 mg
artemether
c [22]
Chinese male and
female patients
with malaria
(n = 11).
Oral multiple doses
of 80 mg
artemether
c,d [21]
Chinese male and
female patients with
malaria
(n = 11).
Oral multiple doses
of 80 mg
artemether
a,c,d [21]
Artemether
CMAX (ng/
mL)
184 ± 100 104 ± 40 118 (112-127) 310 ± 150 157 ± 93
e 133 ± 49
e
TMAX (hr) 1.56 ± 0.68 2.00 (1.00-4.00) 3.00 (1.00-10.0) 1.88 ± 0.21 1.73 ± 0.46
e 2.13 ± 0.49
e
CL/F (L/hr) 257 ± 140 - - 365 ± 190 - -
V/F (L) 666 ± 220 - - 988 ± 520 543 ± 950
e 189 ± 130
e
T1/2 (hr) 2.00 ± 0.71 1.90 ± 0.80 3.10 (1.00-9.60) 2.00 ± 0.59 1.16 ± 0.44 0.860 ± 0.26
TLAG (hr) 0.130 ± 0.23 - - 0.330 ± 0.13 0.480 ± 0.24
e 0.830 ± 0.37
e
AUC0-∞/dose
(hr × ng/
mL/mg)
4.82 ± 2.2 4.00 ± 1.7 5.50 (1.65-22.2) 3.36 ± 1.4 5.73 ± 3.1 6.36 ± 2.5
AUC0-∞ (hr ×
ng/mL)
385 ± 170 320 ± 140 1100 (330-4440) 671 ± 270 1830 ± 1000 2040 ± 800
Dihydro-
artemisinin
CMAX (ng/
mL)
126 ± 46 104 ± 45 379 (162-702) 273 ± 64 161 ± 63
e 105 ± 42
e
TMAX (hr) 1.69 ± 0.59 2.50 (1.00-4.00) 6.00 (2.00-12.0) 1.92 ± 0.13 1.86 ± 0.45
e 2.44 ± 0.44
e
CL/F (L/hr) 269 ± 57 - - - - -
V/F (L) 702 ± 220 - - - 275 ± 230
e 246 ± 99
e
T1/2 (hr) 1.80 ± 0.31 2.10 ± 0.90 10.6 (4.70-19.2) - 0.950 ± 0.42 1.06 ± 0.25
TLAG (hr) 0.250 ± 0.24 - - 0.290 ± 0.10 0.350 ± 0.28
e 0.820 ± 0.54
e
AUC0-∞/dose
(hr × ng/
mL/mg)
3.86 ± 0.76 4.33 ± 1.5 34.5 (4.35-202) 3.94 ± 1.2 9.14 ± 2.0 9.80 ± 4.5
AUC0-∞ (hr ×
ng/mL)
294 ± 58 331 ± 110 6590 (830-38700) 753 ± 230 2930 ± 640 3140 ± 1400
a Fixed oral combination of 80 mg artemether and 120 mg lumefantrine
b administered together with a high-fat meal
c administered on an empty stomach
d administered at 0, 8, 24 and 48 hours
e pharmacokinetic parameter estimates based on the first dose
Values are reported as mean ± SD or as median (range).
Dose normalized exposures were calculated using the published mean or median value for total exposure divided with the mean or median dose.
CMAX = maximum observed plasma drug concentration, TMAX = observed time to reach CMAX, CL/F = oral clearance, V/F = apparent oral volume of distribution,
T1/2 = terminal elimination half-life, TLAG = absorption lag time, and AUC0-∞ = area under the plasma concentration time curve after the first dose to infinity.
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somewhat higher in Chinese patients (n = 22) compared
to the healthy volunteers in this study [21]. Artemether
is rapidly absorbed from the gastrointestinal tract in all
populations and reached maximum concentrations
within two hr. An almost simultaneous detection of the
artemether and dihydroartemisinin in plasma indicates a
rapid in vivo conversion of artemether into its active
metabolite dihydroartemisinin.
All enzymes involved in the metabolism of drugs are
regulated by genes. Because of evolutionary and envir-
onmental factors, there is a remarkable degree of genetic
variability built into a population. Thus, the genetic fac-
tor represents an important cause of inter-individual
variation in drug metabolism. Artemether is metabolized
to its active metabolite dihydroartemisinin by the
enzymes CYP1A2, CYP2B6 and CYP3A4 in humans
[13,14]. CYP3A4 is also expressed in the human small
intestine where it may contribute to pre-systemic meta-
bolic conversation of artemether into dihydroartemisi-
nin. The high extraction ratio over the liver of
artemether should contribute to a substantial first pass
metabolism. A previous study has shown that the
plasma concentration of artemether doubles when co-
administered with a potent CYP3A4 inhibitor (i.e. keta-
conazole). This demonstrates the importance of the
CYP3A4 present in the mucosa cells of the gut wall and
the liver [19]. A wide variation in total CYP3A4 content
exists among individuals which have been attributed to
both environmental and genetic factors. Therefore,
drugs cleared by this isoform are expected to have
highly variable pharmacokinetics [18]. However, the very
large influence on pharmacokinetics of food intake con-
siderably outweighs all other sources of variability for
this drug. In a previous study, a two-fold increase in
relative bioavailability of artemether has been reported
when administered with a fatty meal [23]. Food intake
should attenuate the large variability in oral bioavailabil-
ity of artemether and reduce part of the fluctuations
seen in the plasma concentration profiles. Artemether-
lumefantrine was administered with a glass of milk on
an empty stomach followed by a high fat breakfast one
hr later in the presented study to maximize the relative
bioavailability and prevent erratic absorption profiles in
the healthy volunteers. Even so, there was considerable
inter-individual variability.
Conclusions
In conclusion, the pharmacokinetics of artemether and
dihydroartemisinin was evaluated in 12 healthy male
Pakistani volunteers. Pharmacokinetics were described
in this population and showed similar values as reported
in other populations.
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